Shr3162: Clinical Trials

2 trials of Shr3162, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 1, Terminated 1

Follow Shr3162: new trials by email Literature Review of Shr3162 trials Research Report on Shr3162

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo, Abiraterone acetate and Prednisone - Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 3Active not recruitingJiangsu HengRui Medicine Co., Ltd.4962021-03-182024-12-31
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Fluzoparib, Placebo - Metastatic Pancreatic Cancer
Phase 3TerminatedJiangsu HengRui Medicine Co., Ltd.52020-08-192024-03-28

Conditions studied

Pancreatic Neoplasms (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (2)

Countries

China (2)  ·  Australia (1)  ·  Belgium (1)  ·  Czechia (1)  ·  France (1)  ·  Hungary (1)  ·  Poland (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Yupei Zhao, Ph.D (1)